Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica RemediaLTS:0M8I 59 EV-to-EBIT is 4.06 as of Sep. 08, 2026, which is 9% below its 10-year median of 4.48. GuruFocus rates LTS:0M8I with a GF Score™ of 59/100 and a GF Value™ of lei0.24. The stock has 9 warning signs investors should review. Among 98 Medical Distribution companies, Farmaceutica Remedia ranks better than 91.84% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Farmaceutica Remedia's Enterprise Value for the quarter that ended in Jun. 2026 was lei-14.5 Mil.
Farmaceutica Remedia's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei10.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia EV-to-EBIT Related Terms
Farmaceutica Remedia EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Farmaceutica Remedia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's EV-to-EBIT falls into.
Farmaceutica Remedia's current Enterprise Value is lei41.3 Mil.
Farmaceutica Remedia's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei10.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia (LTS:0M8I) has a EV-to-EBIT of 4.06 as of Sep. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Farmaceutica Remedia and its competitors. This is near median its historical median of 4.48. Over the past decade, Farmaceutica Remedia's EV-to-EBIT has ranged from 0.29 to 904.63. According to the industry distribution chart, Farmaceutica Remedia ranks #8 out of 98 companies in the Medical Distribution industry, placing it in the top 8.2%.
Is Farmaceutica Remedia's EV-to-EBIT too high?
Farmaceutica Remedia's current EV-to-EBIT of 4.06 is near median its 10-year median of 4.48. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 904.63. The Medical Distribution industry median EV-to-EBIT is 11.19. Farmaceutica Remedia's value of 4.06 is 63.7% below this industry median. Based on the distribution chart, Farmaceutica Remedia ranks #8 out of 98 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Farmaceutica Remedia has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #8 out of 98 companies for EV-to-EBIT. This places Farmaceutica Remedia in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 11.19. Farmaceutica Remedia's value of 4.06 is 63.7% below this benchmark. Historically, Farmaceutica Remedia's own EV-to-EBIT has ranged from 0.29 to 904.63 over the past decade. While the company's 10-year median is 4.48 vs. the industry median of 11.19, Farmaceutica Remedia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.19, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmaceutica Remedia's current EV-to-EBIT of 4.06 is 63.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current EV-to-EBIT is 4.06, which is near median its own 10-year median of 4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Farmaceutica Remedia (LTS:0M8I) has a current EV-to-EBIT of 4.06. The stock's GF Value™ is lei0.24, compared to a current price of lei0.25 — trading 4.2% above its estimated fair value. The current EV-to-EBIT is 4.06, which is near median its 10-year median of 4.48 and 63.7% below the Medical Distribution industry median of 11.19. Farmaceutica Remedia's overall GF Score™ is 59/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Farmaceutica Remedia (LTS:0M8I), the current EV-to-EBIT is 4.06 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (LTS:0M8I) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.25 is trading 4.2% above its estimated GF Value™ of lei0.24.
Key valuation signals for LTS:0M8I:
EV-to-EBIT: 4.06 (near median its 10-year median of 4.48)
GF Value™: lei0.24 vs. price of lei0.25 (4.2% above fair value)
Industry Position: 63.7% below the Medical Distribution median (#8 of 98)
No single metric tells the full story. See the LTS:0M8I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
59GF Score
Get the complete analysis for LTS:0M8I
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M8I has been successfully added to your 
